Pharmacokinetics and organ distribution of methotrexate in the rat
- PMID: 7312939
- DOI: 10.1159/000137531
Pharmacokinetics and organ distribution of methotrexate in the rat
Abstract
After intravenous injection of 31 mg/kg methotrexate (MTX), its concentrations were determined in plasma, liver, kidney, bone marrow, stomach, duodenum, jejunum, colon and muscle up to 23 days, using an enzymatic assay. Plasma pharmacokinetics were described by a triexponential function, with a terminal half-life of 4.2 h. Up to 1.5 h after injection, the initial rapid decline of MTX concentrations in bone marrow, kidney, and liver roughly paralleled that in plasma. The terminal half-life of MTX in bone marrow was greatly prolonged (37 h), while MTX remained nearly constant in liver (0.57 microgram/ml) and kidney (0.53 microgram/ml) from 6 h to 23 days. In the intestines, luminal as well as tissue MTX concentrations were determined. The stomach showed a triexponential decay of tissue MTX and low luminal concentrations throughout. In the duodenum, the middle of jejunum, and the colon tissue MTX seemed to follow a bi- or triexponential function. However, high luminal concentrations due to MTX biliary excretion, when reaching a given intestinal portion, increased the MTX tissue concentration in this segment.
Similar articles
-
Evidence of nonlinear pharmacokinetics of methotrexate in the rat.Pharmacology. 1982;25(1):51-6. doi: 10.1159/000137723. Pharmacology. 1982. PMID: 7122690
-
Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.Cancer Chemother Pharmacol. 1986;18(2):111-6. doi: 10.1007/BF00262278. Cancer Chemother Pharmacol. 1986. PMID: 3791556
-
Effect of nutritional status on the hepatobiliary excretion of methotrexate in the rat.Cancer Treat Rep. 1983 Mar;67(3):253-7. Cancer Treat Rep. 1983. PMID: 6403239
-
In vivo methotrexate kinetics and metabolism in human hematopoietic cells. Clinical significance of methotrexate concentrations in erythrocytes.Dan Med Bull. 1990 Feb;37(1):22-40. Dan Med Bull. 1990. PMID: 2178886 Review.
-
Pharmacokinetic studies of interferons.Pharmacol Ther. 1981;13(3):421-40. doi: 10.1016/0163-7258(81)90023-1. Pharmacol Ther. 1981. PMID: 6169099 Review. No abstract available.
Cited by
-
Methotrexate kinetics in myeloid bone marrow cells and peripheral neutrophils.Cancer Chemother Pharmacol. 1987;19(1):42-6. doi: 10.1007/BF00296254. Cancer Chemother Pharmacol. 1987. PMID: 3815725
-
Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.Cancer Chemother Pharmacol. 1985;15(2):115-20. doi: 10.1007/BF00257520. Cancer Chemother Pharmacol. 1985. PMID: 4017160
-
A Semi-Mechanistic Mathematical Model of Immune Tolerance Induction to Support Preclinical Studies of Human Monoclonal Antibodies in Rats.Pharmaceutics. 2025 Jun 27;17(7):845. doi: 10.3390/pharmaceutics17070845. Pharmaceutics. 2025. PMID: 40733054 Free PMC article.
-
Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.Cell Mol Immunol. 2017 Feb;14(2):146-179. doi: 10.1038/cmi.2016.39. Epub 2016 Oct 10. Cell Mol Immunol. 2017. PMID: 27721455 Free PMC article. Review.
-
Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate.J Pharmacokinet Pharmacodyn. 2014 Apr;41(2):159-71. doi: 10.1007/s10928-014-9354-4. Epub 2014 Mar 21. J Pharmacokinet Pharmacodyn. 2014. PMID: 24651961
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources